Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Effect of induction chemotherapy on lung function measured by spiroergometry and 6-Minute walking test in patients affected by non-small cell lung cancer (NSCLC)
01.01.2018Lung cancer is one of the most common cancers in the world and the leading cause of cancer-related mortality. At diagnosis, approximately 40% of patients are already at an advanced stage, and a third have locally advanced disease (stage III). Stage I...
Grundlagenforschung - 01.01.2018 - 31.12.2020
Automatisch geschlossen
Mitarbeiter/innen: Baty Florent, Brutsche Martin, Kern Lukas, Maeder Micha, Früh Martin
A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected ad-vanced solid tumors and non-Hodgkin lymphoma
05.10.2017This is a multi-center, open label, phase 2 study to evaluate efficacy of the NIR178 and PDR001 combination in NSCLC, other solid tumors, and diffuse large B-cell lymphoma (DLBCL). The study has three parts: part 1: Multi-arm Bayesian adaptive signal...
Klinische Forschung - 05.10.2017 - 30.06.2019
Automatisch geschlossen
Projektleitung: Jörger Markus
SAKK 17/16: Lurbinectedin Monotherapy in Pa-tients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial
29.09.2017Malignant mesothelioma arises from the mesothelial cells of the pleural, peritoneal or pericardial lining and is often associated with asbestos exposition (Robinson, 2005). There is no cure for most malignant mesotheliomas and the scope of all three...
Klinische Forschung - 29.09.2017 - 29.09.2021
Automatisch geschlossen
Projektleitung: Früh Martin
Randomisierte, doppelblinde, placebokontrollierte Pha-se III-Studie zu Rovalpituzumab Tesirin als Erhaltungs-therapie nach einer Erstlinienchemotherapie auf Platin-basis bei Studienteilnehmern mit ausgebreitetem (exten-sive-stage) kleinzelligem Bronchialkarzinom (MERU)
22.09.2017Industrie gesponserte Studie zur Evaluation der Wirksamkeit (hinsichtlich OS und PFS) von Rovalpituzumab Tesirin beim SCLC, eingesetzt als Erhaltungstherapie nach Erstli-nientherapie. Rovalpituzumab Tesirin ist ein Antikörper-Wirkstoff Konju-gat, wob...
Klinische Forschung - 22.09.2017 - 31.03.2019
Automatisch geschlossen
Projektleitung: Früh Martin
The MENAC Trial - A randomised, open-label trial of a multimodal intervention (multimodal = exercise, nutrition and anti-inflammatory medication) versus standard care in cancer patients with cachexia
24.08.2017Cachexia is a common detrimental consequence of cancer limiting therapy, quality of life and survival. There is no standard treatment available and its complex multifactorial pathophysiology requires multimodal treatment. Based on promising phase II...
Klinische Forschung - 24.08.2017 - 31.05.2020
Automatisch geschlossen
Projektleitung: Strasser Florian, Domeisen Benedetti Franzisca
Mitarbeiter/innen: Attoun-Knobel Suzanne, Behnke Nadine
CLL13-TRIAL OF THE GCLLSG IN COOPERATION WITH HOVON, NORDIC CLL STUDY GROUP AND SAKK (THE GA101 IBRUTINIB ABT101 (GAIA) TRIAL): A PHASE 3 MULTICENTER, RANDOMIZED, PROSPECTIVE, OPEN-LABEL TRIAL OF STANDARD CHEMOIMMUNOTHERAPY (FCR/BR) VERSUS RITUXIMAB PLUS VENETOCLAX (RVE) VERSUS OBINUTUZUMAB (GA101) PLUS VENETOCLAX (GVE) VERSUS OBINUTUZUMAB PLUS IBRUTINIB PLUS VENETOCLAX (GIVE) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL(17P) OR TP53 MUTATION
17.07.2017Chemoimmunotherapy is the standard of care in first-line treatment of CLL patients without del17p or TP 53 mutation; physically fit patients are treated with fludarabine, cyclophosphamide and rituximab (FCR)1. Due to the high risk of severe neutropen...
Klinische Forschung - 17.07.2017 - 30.06.2020
Automatisch geschlossen
Projektleitung: Baumann Michael
QLQ-CAX24 Phase4
17.07.2017The aim of the present study is to test the scale structure, reliability, responsiveness to change and validity of the EORTC QLQ-CAX24 in conjunction with the EORTC QLQ-C30 in people diagnosed with cancer cachexia with different primary cancer diagno...
Klinische Forschung - 17.07.2017 - 01.10.2017
Automatisch geschlossen
Projektleitung: Strasser Florian
Mitarbeiter/innen: Domeisen Benedetti Franzisca, Attoun-Knobel Suzanne
Preclinical investigation of cardiotoxicity as a clinically important side effect of proteasome inhibitor-based therapy
01.07.2017Carfilzomib is the recently approved second generation proteasome inhibitor for multiple myeloma therapy. Carfilzomib has superior clinical activity than the first generation drug, bortezomib, putatively due to less off-target activity and an altered...
Grundlagenforschung - 01.07.2017 - 30.06.2018
Automatisch geschlossen
Projektleitung: Besse Lenka
Mitarbeiter/innen: Mendez-Lopez Max
ETOP 10-16 BOOSTER: A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with con-firmed EGFRm and T790M
15.06.2017First-generation EGFR tyrosine kinase inhibitors provide significant clinical benefit in patients with advanced EGFR-mutant (EGFRm) non–small cell lung carcinoma (NSCLC). However, all patients ultimately develop disease progres-sion, driven – as the...
Klinische Forschung - 15.06.2017 - 30.11.2019
Automatisch geschlossen
Projektleitung: Früh Martin
HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cy-cles of escalated BEACOPP with 6 cycles of BrECADD
09.06.2017With the establishment of polychemotherapy and the con-tinuous advancements in radiotherapy, Hodgkin lymphoma has meanwhile become a malignant oncological disease in adults with one of the best prognoses of all. The outcome improvements in Hodgkin ly...
Klinische Forschung - 09.06.2017 - 30.09.2021
Automatisch geschlossen
Projektleitung: Hitz Felicitas
SAKK 19/16:Binimetinib, pemetrexed and cisplatin, followed by maintenance with binimetinib and pemetrexed, in patients with advanced non-small cell lung cancer with KRAS mutationsA multicenter phase IB trial
25.04.2017There is a need for more effective therapies for patients with advanced NSCLC driven by the RAS/MEK/ERK pathway. These tumors are generally aggressive, are almost exclusively of non-squamous histology, and represent the largest group of patients with...
Klinische Forschung - 25.04.2017 - 30.11.2019
Automatisch geschlossen
Projektleitung: Früh Martin
SAKK 35/15: A phase I trial of obinutuzumab in combination with venetoclax in previously untreated follicular lymphoma patients
03.04.2017Follicular lymphoma is an indolent yet incurable lymphoma characterized by a relapsingremitting course with initial responses to standard therapies, invariably followed by shorter disease free intervals. In recent years, significant treatment improve...
Klinische Forschung - 03.04.2017 - 30.09.2020
Automatisch geschlossen
Projektleitung: Hitz Felicitas
SAKK 41/16: Neoadjuvant treatment with Regorafenib and Capecitabine combined with radiotherapy in locally advanced rectal ca cer. A multicenter phase Ib trial (RECAP)
07.03.2017Despite treatment of locally advanced rectal cancer re-lapses are frequent. Several attempts to improve these results with therapy intensification have shown modest effect on disease free survival (DFS) and overall survival (OS). Recent studies with...
Klinische Forschung - 07.03.2017 - 31.07.2019
Automatisch geschlossen
Projektleitung: Jörger Markus
SAKK 24/14: Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative EGFR positive breast cancer – A multicenter single arm phase II trial
07.11.2016Advanced triple negative breast cancer (TNBC) is a highly chemosensitive disease displaying a dismal short-term prognosis with more than three quarters of patients in pro-gression 12 months after the initiation of conventional chemotherapy. Approxima...
Klinische Forschung - 07.11.2016 - 31.05.2023
Laufend
Projektleitung: Weder Patrik
HIV-Proteaseinhibitoren als Basis für Krebstherapie: Verständnis des Mechanismus, Identifikation der Targets, Entwicklung wirksamerer Substanzen
01.11.2016Proteasominhibitor-Resistenz ist ein wichtiger unmet clinical need beim Multiplen Myelom (MM). Die Aktivität von next generation therapy (Daratumumab, Carfilzomib, Pomalidomid) ist hier bei ca. 30 % Partialremissionen (PR). Wir haben in vitro durch...
Grundlagenforschung - 01.11.2016 - 31.10.2018
Automatisch geschlossen
Projektleitung: Driessen Christoph
Mitarbeiter/innen: Kraus Marianne, Bader Juergen, Besse Lenka, Besse Andrej
SAKK 30/15; HOVON 135: A randomized phase II multicenter study to assess the to erability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged ≥ 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFITolder AML/high-risk MDS patients
27.10.2016This is a prospective, open label, multicenter study that is conducted in the frame of a masterprotocol with multiple parallel randomized phase II arms. The scheme of this design consists of one arm with the standard treatment for AML (the 10-day dec...
Klinische Forschung - 27.10.2016 - 31.07.2018
Automatisch geschlossen
Projektleitung: Fehr Martin
CA209-577: A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 577)
21.10.2016CA209577 is a phase 3, randomized, double-blind, placebo controlled study of adjuvant nivolumab in subjects with resected esophageal cancer (EC), or gastroesophageal junction (GEJ) cancer who have received chemoradiother-apy(CRT) followed by surgery....
Klinische Forschung - 21.10.2016 - 30.11.2017
Automatisch geschlossen
Projektleitung: Weisshaupt Christian
PhenoTox: Hunting the missing heritability of early-onset fluoropyrimdine-related toxicity in cancer patients: an observational multi-center study
04.10.2016In cancer patients receiving fluoropyrimidine-based chemo-therapy, there is extensive inter-individual variability in plasma drug concentrations and the severity of chemo-therapy-related toxicity. A strong association has been shown for plasma concen...
Klinische Forschung - 04.10.2016 - 04.10.2020
Automatisch geschlossen
Projektleitung: Jörger Markus
CA209451: Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy. CheckMate 451
07.09.2016This is a randomized, double-blind, three-arm, multicenter, Phase 3 study in adult subjects with ED-SCLC, who achieve Stable Disease, Partial Response or Complete Response after completion of platinum based first line chemotherapy. Approximately 810...
Klinische Forschung - 07.09.2016 - 30.11.2020
Automatisch geschlossen
Projektleitung: Früh Martin
An open-label Phase 1/2a study of BAL101553 adminis-tered as 48-hour intravenous infusions in adult patients with advanced solid tumors
19.08.2016The primary objectives of this study are to determine the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of BAL101553, administered as an intravenous (IV) infusion over 48 hours on study Days 1, 8 and 15 of a 28-day...
Klinische Forschung - 19.08.2016 - 31.01.2018
Automatisch geschlossen
Projektleitung: Jörger Markus